Leaving INTR@PID website

You are leaving INTR@PID Clinical Trials page. This link will take you to a website where our Terms of Use do not apply. Merck Healthcare KGaA has no control over the contents and policies of these sites or resources, and accepts no responsibility for your use of them.

Please Confirm

This website is an information resource intended only for Healthcare Professionals from U.S., Puerto Rico and Canada who are interested in information on Clinical Research and EMD Serono sponsored clinical trials.

By clicking "I am a healthcare professional" you are declaring and confirming that you are a Healthcare Professional inside the U.S., Puerto Rico and Canada and have read and understood this disclaimer.

Immuno-Oncology and Bintrafusp Alfa

What is immuno-oncology?

  • Immuno-oncology is an innovative approach to cancer therapy that utilizes the body’s own immune system to fight cancer
  • Advances in the field of immuno-oncology have allowed us to approach cancer therapy in a new and exciting way, with research suggesting we may be able to block immunosuppressive pathways in the tumor microenvironment1

 

What is bintrafusp alfa?

  • Bintrafusp alfa is an investigational bifunctional fusion protein currently being investigated for the treatment of various advanced solid tumors
  • Bintrafusp alfa is designed to simultaneously block two immunosuppressive mechanisms, TGF-β (transforming growth factor β) and PD-L1 (programmed death-ligand 1)2
  • By targeting these pathways, bintrafusp alfa aims to control tumor growth by potentially restoring and enhancing the anti-tumor response

 

Rationale for the dual targeting of TGF-β and PD-L1

 
Bintrafusp alfa is under clinical investigation and has not been proven to be safe and effective. There is no guarantee that bintrafusp alfa will be approved in the sought-after indication by any health authority worldwide.

 

References:

1. Finn OJ. Ann Oncol. 2012;23(Suppl 8):6-9.

2. Lan Y, et al. Sci Transl Med. 2018;10:eaan5488.